🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Non-Hodgkin Lymphoma, Adult

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma NCT05798897Phase 17 sites📍 Duarte📍 Aurora📍 Denver Marker Therapeutics, Inc. · Tests: MT-601 A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) NCT06742996Phase 3145 sites📍 Birmingham📍 Tucson📍 Fresno BeOne Medicines · Tests: Sonrotoclax, Zanubrutinib, Placebo A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma NCT05533775Phase 1, Phase 230 sites📍 Birmingham📍 Oakland📍 Oakland Hoffmann-La Roche · Tests: Obinutuzumab, Glofitamab, Rituximab, Ifosfamide, Carboplatin A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) NCT01351545n/a142 sites📍 Birmingham📍 Gilbert📍 Phoenix Center for International Blood and Marrow Transplant Resear… · Tests: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers NCT05770037Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Alectinib Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081NA1 site📍 Beijing Peking University People's Hospital · Tests: Senl_B19 autologous CAR-T (S1904) treatment A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas NCT05685173Phase 120 sites📍 Duarte📍 Santa Monica📍 Louisville Regeneron Pharmaceuticals · Tests: Odronextamab, REGN5837 Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites📍 Duarte📍 Los Angeles📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-1607, Paclitaxel A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma. NCT06383338Phase 11 site📍 Melbourne Murdoch Childrens Research Institute · Tests: Omeprazole, Dextromethorphan Development of Pressure Sensor Based Dementia and Fall Prevention Program for Older Adults NCT06664229NA1 site📍 Seoul Sunmi Song · Tests: Fall and dementia prevention exercise Cognitive Screening Made Easy for PCPs - Administrative Supplement NCT06928298NA3 sites📍 Austin📍 Austin📍 San Antonio University of Texas at Austin · Tests: RACS app T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) NCT06343311Phase 1, Phase 25 sites📍 Sacramento📍 Cleveland📍 Portland Estrella Immunopharma, Inc. · Tests: EB103 Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma NCT06091865Phase 3194 sites📍 Scottsdale📍 Los Angeles📍 Orange Regeneron Pharmaceuticals · Tests: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine Phosphatidylethanol and Other Ethanol Consumption Markers NCT06747364NA2 sites📍 Denton📍 San Antonio The University of Texas Health Science Center at San Antonio · Tests: Alcohol (Ethanol) Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia NCT05869279Phase 1, Phase 21 site📍 Bergamo Fondazione Matilde Tettamanti Menotti De Marchi Onlus · Tests: CARCIK-CD19 Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NCT07520006Phase 1, Phase 26 sites📍 Aurora📍 Coral Gables📍 Eugene Nurix Therapeutics, Inc. · Tests: NX-5948, venetoclax, rituximab, obinutuzumab A Study of ARC-02 in B-cell NHL NCT07691606Phase 129 sites📍 Los Angeles📍 Louisville📍 New York Taiho Oncology, Inc. · Tests: ARC-02, Rituximab Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies NCT07648264Phase 360 sites📍 Orange📍 Denver📍 Coral Springs CSL Behring · Tests: IgPro20 A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas NCT05773040Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: JV-213, Leukapheresis A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) NCT06124157Phase 2161 sites📍 Birmingham📍 Phoenix📍 Tucson National Cancer Institute (NCI) · Tests: Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127 Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801n/a6 sites📍 Aurora📍 Atlanta📍 Cincinnati Children's Hospital Medical Center, Cincinnati · Tests: 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid)… Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR NCT03676504Phase 1, Phase 22 sites📍 Heidelberg📍 Heidelberg University Hospital Heidelberg · Tests: CD19.CAR T Cells, Fludarabine, Cyclophosphamide A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma NCT06149286Phase 3171 sites📍 Los Angeles📍 Plantation📍 Indianapolis Regeneron Pharmaceuticals · Tests: Odronextamab, Lenalidomide, Rituximab Study of Out of Specification for Tisagenlecleucel NCT04094311Phase 355 sites📍 Hamilton📍 Ottawa📍 Toronto Novartis Pharmaceuticals · Tests: CTL019 The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL NCT03509961Phase 224 sites📍 Birmingham📍 Phoenix📍 Duarte Pediatric Transplantation & Cellular Therapy Consortium · Tests: NGS-MRD, Myeloablative allogeneic HCT with a non-TBI conditioning regimen
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy